Effect of *Curcuma Longa* Rhizome Extract on Fasting Blood Sugar Levels and HbA1C in Type 2 Diabetes Mellitus: A Meta-Analysis

**Riska Fajar Fatony**\(^1\), **Didik Gunawan Tamtomo**\(^2\), **Hanung Prasetya**\(^3\)

\(^1\)Masters Program in Public Health, Universitas Sebelas Maret
\(^2\)Faculty of Medicine, Universitas Sebelas Maret
\(^3\)Study Program of Acupuncture, Health Polytechnics, Ministry of Health Surakarta

**ABSTRACT**

**Background:** Diabetes mellitus (DM) is a metabolic disease that is developing into a serious global problem. Diabetes mellitus is characterized by an increase in blood levels that are more than the normal reference. In type 2 DM generally occurs due to reduced insulin secretion and sensitivity over time. Control of blood sugar levels can improve the patient's quality of life. This study aimed to analyze the effect of *curcuma longa* rhizome extract on fasting blood sugar levels and HbA1C in patients with type 2 diabetes.

**Subjects and Method:** This was a meta-analysis of a number of randomized controlled trials. The articles were obtained from PubMed, Google Scholar, Springerlink, BMJ, and ScienceDirect databases, published from 2010-2020. The article search was carried out by considering the eligibility criteria defined using the PICO model. P: Type 2 diabetes patients, I: *Curcuma longa* rhizome extract, C: Placebo, and O: Fasting blood sugar levels and HbA1C. The keywords to find articles are as follows: "Curcuma longa", OR "Curcumin" OR "Tumeric" OR "Curcuma" AND "Fasting blood glucose" AND "HbA1C" OR "Glicemic" OR "Diabetes Mellitus" AND "Randomized Controll Trials". Articles were collected using PRISMA flow diagrams. Articles were analyzed using the Review Manager 5.3 application.

**Results:** A total of 14 articles were reviewed in this study. Meta-analysis of 12 articles showed that the *curcuma longa* rhizome extract reduced fasting blood sugar levels (Standardized Mean Difference= -0.48; 95% CI= -0.61 to -0.34; p < 0.001). The meta-analysis of 11 articles showed that administration of *curcuma longa* rhizome extract decreased HbA1C levels (Standardized Mean Difference= -0.40; 95% CI = -0.59 to -0.20; p < 0.001). This meta-analysis combines primary studies from Iran, Japan, Thailand, China, Mexico, Brazil, and Australia.

**Conclusion:** *Curcuma longa* rhizome extract reduces fasting blood sugar and HbA1C levels in patients with type 2 diabetes.

**Keywords:** Curcuma longa, Fasting blood sugar levels, HbA1C, diabetes mellitus type 2, randomized controlled trial

**Correspondence:**
Riska Fajar Fatony, Masters Program in Public Health, Universitas Sebelas Maret. Jl. Ir. Sutami 36A, Surakarta 57126, Central Java.
Email: respatieka10@gmail.com.
2017 to 629 million in 2045 (IDF, 2017). Indonesia is in the 7th rank of the top 10 countries with the highest number of DM sufferers with a prevalence of 8.6% of the total population. This number is estimated to continue to increase from 8.4 million people in 2000 to around 21.3 million people in 2030 (Riskesdas, 2018).

Diabetes mellitus type 2 continues to develop due to the influence of cultural, economic, social, aging changes, diet such as increased consumption of processed foods and sweet drinks, reduced physical activity, unhealthy lifestyles, and behavior patterns. (WHO, 2019).

Complications that occur due to type 2 diabetes can include disorders of the blood vessels, both macrovascular (coronary heart disease, stroke, and peripheral vascular disease) and microvascular (retinopathy, neuropathy, and nephropathy). This disorder can occur in patients with type 2 diabetes who have long suffered from the disease or type 2 diabetes which has just been diagnosed (David, 2020). DM type 2 can be diagnosed through 4 criteria, namely checking fasting blood sugar levels, random blood sugar, HbA1C, and tests. Oral Glucose Tolerance (TTGO). (Perkeni, 2019).

The management of DM begins with implementing a healthy lifestyle (improved nutrition and physical activity) along with pharmacological interventions with oral anti-hyperglycemia drugs and / or injections. In addition to pharmacological therapy, there have been many studies related to the use of herbs which have been found to be used as alternative therapeutic options in type 2 DM patients, one of which is curcuma longa (Lim, 2016).

Curcuma longa in Indonesia itself is known as turmeric and has been used for generations as a traditional medicine. Curcuma longa is useful as an antioxidant, anti-inflammatory, anti-diabetic, and immunomodulatory, curcuma longa has also been shown to relieve diabetes symptoms and slow its development (Roxo et al., 2019). Several studies related to curcuma longa have proven that giving curcuma longa rhizome extract results in significant changes in blood sugar levels in type 2 DM patients (Shi et al., 2019).

Management of DM in general is to improve the patient's quality of life. In the short term, it aims to relieve complaints of DM symptoms and reduce the risk of acute complications. In the medium and long term, it is to prevent and inhibit the progression of complicating microangiopathies and macroangiopathies. The ultimate goal of managing DM is to reduce morbidity and mortality. To achieve this goal, one of the steps is the need to control blood sugar levels (Perkeni, 2015).

This study aimed to examine the effect of curcuma longa rhizome extract on fasting blood sugar levels and HbA1C in type 2 DM.

SUBJECTS AND METHOD

1. Study Design
This was a systematic review and meta-analysis. The articles used in this study were obtained from several databases including PubMed, Google Scholar, Springerlink, BMJ med and Sciedirect. The keywords to find articles are as follows: "Curcuma longa", OR "Curcumin" OR "Tumerie" OR "Curcuma" AND "Fasting blood glucose" AND "HbA1C" OR "Glicemic" OR "Type 2 Diabetes Mellitus" AND "Randomized Controll Trials ".

2. Inclusion Criteria
The articles included in this study are full text with Randomized Controll Trials study and in English. The appropriate article should mention the population of type 2 DM patients, the intervention giving Curcuma longa rhizome extract and the outcome contained fasting blood sugar and HbA1C levels. Articles published in 2010-2020 with the results of the Mean Difference and Standard deviation.

3. Exclusion Criteria
The articles published in this study were articles with type 1 DM patients. The articles used an observational study design and used a sample of test animals. The comparison did
not use a placebo but used other herbal antidiabetic substances. There are other comorbidities.

4. Operational Definition of Variables
The article search was carried out by considering the eligibility criteria defined using the PICO model. The population in the study was type 2 DM patients with intervention in the form of giving curcuma longa rhizome extract. Meanwhile, the comparison is placebo and outcomes in the form of fasting blood sugar and HbA1C levels.

Curcuma longa rhizome extract which is processed in the form of capsules or other oral preparations. The measuring tool is a questionnaire.

Checking blood sugar levels is carried out after not consuming calories for at least 8 hours before the examination, the unit of measurement is in mg/dL, the measuring instrument is a spectrophotometer.

Laboratory tests of HbA1C levels in blood plasma with % HbA1C units, carried out at least 2 months after the intervention, the measuring instrument is a spectrophotometer.

5. Data Analysis
Data processing was carried out by the RevMan 5.3 by calculating the effect size and heterogeneity to determine which research models were combined and formed the final meta-analysis result.

RESULTS
The articles searched through a database with journals can be seen in Figure 1. Figure 2 shows the area of articles obtained from the continents of Asia, Australia, and America.

![Figure 1. PRISMA flow diagram](www.theijmed.com)

Articles identified through database search (n= 3634) → Delete duplicate data (n = 356)

Articles issues (n = 3023)
- Not RCT = 1304
- Irrelevant title = 1685
- Languages other than English = 21
- Not full text = 13

Articles issued with reasons (n = 242)
- The patient was not diagnosed with type 2 diabetes = 119
- Type 2 DM patients with comorbidities = 6
- Research on test animals = 36
- Comparators not placebo = 15
- The intervention is not curcuma longa extract = 30
- Curcuma longa extract intervention +
  other antidiabetic herbs = 13
- Additional insulin therapy = 4
- The article does not include mean SD = 6
- Outcome did not contain blood sugar levels and / or HbA1C = 10
- The time span of the study is too long or short = 3
Figure 2. Map of the research area of *Curcuma longa* rhizome extract on blood sugar levels in type 2 Diabetes Mellitus patients
The results of the quality assessment study on the effect of extra *Curcuma longa* rhizome on fasting blood sugar and HbA1C levels.

Table 1. Critical Appraisal Skills Checklist for RCT

| Checklist                                                                 | Adab et al (2019) | Asadi et al (2019) | Alvarenga et al (2020) | Chuengsamarn et al (2014) | Hodei et al (2019) | Funamoto et al (2019) | Jimenez et al (2015) | Mirzabeigi et al (2015) | Mokhtari et al (2020) | Na et al (2012) | Panahi et al (2017) | Rahimi et al (2016) | Vanaie et al (2019) | Thota et al (2019) |
|---------------------------------------------------------------------------|-------------------|--------------------|------------------------|---------------------------|-------------------|---------------------|---------------------|-----------------------|-------------------|----------------|----------------|----------------|----------------|----------------|
| Does the research clearly address the focused statement / problem?       | 1                 | 1                  | 1                      | 1                         | 1                 | 1                   | 1                   | 1                     | 1                 | 1              | 1              | 1              | 1              | 1               |
| Is the Randomized Controlled Trial research method suitable for answering research questions? | 1                 | 1                  | 1                      | 1                         | 1                 | 1                   | 1                   | 1                     | 1                 | 1              | 1              | 1              | 1              | 1               |
| Are there enough subjects in the study to establish that the findings were not made by chance? | 1                 | 1                  | 1                      | 1                         | 1                 | 1                   | 1                   | 1                     | 1                 | 1              | 1              | 1              | 1              | 1               |
| Are subjects randomly allocated to the experimental and control groups? If not, could this be biased? | 1                 | 1                  | 1                      | 1                         | 1                 | 1                   | 1                   | 1                     | 1                 | 1              | 1              | 1              | 1              | 1               |
| Are inclusion / exclusion criteria used?                                 | 1                 | 1                  | 1                      | 1                         | 1                 | 1                   | 1                   | 1                     | 1                 | 1              | 1              | 1              | 1              | 1               |
| Were the two groups comparable?                                          | 1                 | 0                  | 1                      | 1                         | 0                 | 0                   | 0                   | 0                     | 1                 | 0              | 0              | 0              | 0              | 0               |
| Question                                                                 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
|------------------------------------------------------------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Are variable at study entry?                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Are objective and unbiased outcome criteria?                          | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Are objective and validated measurement methods used to measure the   | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| results? If not, were the results scored by someone who did not know  |   |   |   |   |   |   |   |   |   |   |   |   |   |
| the group assignment (i.e. was the grading blended)?                  |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Is the effect size practically relevant?                              | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| How precise is the estimated effect?                                  | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 |
| Are there any confidence intervals?                                   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Could there be confounding factors that have not been taken into      | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| account?                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Are the results applicable to your research?                          | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

Total: 12, 11, 11, 11, 10, 10, 10, 11, 12, 10, 11, 11, 11, 10
### Article Summary
The effect of curcuma longa rhizome extract on fasting blood sugar levels and HbA1c in patients with type 2 diabetes mellitus

#### Table 2. Descriptions of primary studies included in the meta-analysis

| Author (year)       | Titles                                                                 | Country | Study Design | Sample | Population | Intervention | Comparison       | Outcome                     |
|---------------------|------------------------------------------------------------------------|---------|--------------|--------|------------|--------------|------------------|------------------------------|
| Adab et al. (2019)  | Effect of turmeric on glycemic status, lipid profile, hs-CRP, and total antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients | Iran    | RCT          | I=39   | C= 36      | Pasien DM tipe 2 | 2100 mg ekstrak curcuma longa perhari selama 10 minggu | Plasebo                      | GDP (mg/dL) C = 139.41 ± 41.57 HbA1C (%) I = 7.28 ± 1.59 C = 7.04 ± 0.98 |
| Asadi et al. (2019) | Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus | Iran    | RCT          | I=40   | C=40       | Pasien DM tipe 2 | 2400 mg nano-carcum setara 1000 mg ekstrak curcuma longaperhari selama 10 minggu | Plasebo                      | GDP (mg/dL) I = 165.7±52.3 C = 184.9±58.1 HbA1C (%) I = 8.18±1.96 C = 9.22±1.72 |
| Alvarenga et al. (2020) | Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients | Brazil  | RCT          | I= 14  | C= 14      | Pasien DM tipe 2 | 2500 mg ekstrak curcuma longaper hari selama 12 minggu | Plasebo                      | GDP (mg/dL) I = 139.0 ± 58.2 C = 106.8 ± 32.5 HbA1C (%) I = 6.8 ± 1.0 C = 6.3 ± 0.9 |
| Chuengsamarin et al. (2012) | Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract | Thailand| RCT          | I = 107 | C = 106    | Pasien DM tipe 2 | 1500 mg ekstrak curcuma longaper hari selama 12 minggu | Plasebo                      | GDP (mg/dL) I = 123.2 ± 25 HbA1C (%) I = 6.5±0.9 C = 7±1.1 C = 139.3 ± 35.9 HbA1C (%) I = 6.2±0.5 C = 6.5±0.3 |
| Funamoto et al. (2019) | Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus | Japan   | RCT          | I=15   | C=18       | Pasien DM tipe 2 | 180 mg nano-curcumin setara 750 mg ekstrak curcuma longa/hari selama 12 minggu | Plasebo                      | GDP (mg/dL) I = 6.3 ± 0.5 C = 6.5 ± 0.3 |
| Author (year) | Titles                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Country | Study Design | Sample | Population | Intervention                                                                 | C | Comparison | Outcome                                                                                                                                 |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------|--------|------------|------------------------------------------------------------------------------|---|------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Hodaeiet al. (2019) | The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Iran   | RCT         | I=21   | Pasien DM tipe 2                                                                 | 1500 mg ekstrak curcuma longa per hari selama 10 minggu | Plasebo     | GDP (mg/dL) I = 153±33 C = 147±40.4 HbA1C (%) I = 11±2 C = 11.1±1. GDP (mg/dL) I= 122.50 ± 35.68 C=116.46 ± 24.96 |
| Mirzabeigi et al. (2015) | The Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors Randomized, Double-blind, Placebo-controlled                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Iran   | RCT         | I= 17  | Type 2 DM patients                                                                | 1500 mg of curcuma longa extract per day for 10 weeks | Placebo     | GDP (mg/dL) |
| Mokhtari et al. (2020) | The effects of curcumin intake on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Iran   | RCT         | I= 25  | Type 2 DM patients                                                                | 80 mg of nanocurcumin equivalent to 325 mg of curcuma longa extract per day for 12 weeks | Placebo     | GDP (mg/dL) I= 131±31.9 C= 147±37.1 HbA1C (%) I = 7±2 C = 8±2.9 |
| Na et al. (2012) | Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | China  | RCT         | I= 50  | Type 2 DM patients                                                                | 300 mg of curcuma longa extract per day for 12 weeks | Placebo     | GDP (mg/dL) I= 120.9±8.8 C= 122.6 ±11.7 |
| Jimenez at al. (2012) | The effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic proteinuric nephropathy type 2 DM patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Mexico | RCT         | I=28   | Nephropathy type 2 DM patients                                                  | 320 mg of curcuma longa extract per day for 10 weeks | Placebo     | GDP (mg/dL) I = 154 ± 34 C = 171 ± 26 HbA1C (%) I = 6.5±1 C = 7.3±0.8 |
| Panahiet al (2017) | Effects of Curcuminoids Plus Piperine on Glycemic, Hepatic and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Iran   | RCT         | I=50   | Type 2 DM patients                                                                | 500 mg of curcuma longa extract per day for 12 weeks | Placebo     | GDP (mg/dL) I = 120.29±38.01 |
| Rahimi et al (2016) | The effect of nano-curcumin on HbA1c, fasting blood glucose, and Lipid Profile in Diabetic Patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Iran   | RCT         | I=35   | Type 2 DM patients                                                                | 80 mg nanocurcumin                                    | Placebo     | GDP (mg/dL) I = 120.29±38.01 |
### Table 1: Summary of Studies on the Effect of Curcuma Longa Rhizome Extract on Fasting Blood Sugar Levels

| Author (year) | Titles                                                                 | Country | Study Design | Sample | Population | P | Intervention | C | Comparison | O | Outcome |
|---------------|------------------------------------------------------------------------|---------|--------------|--------|------------|---|--------------|---|------------|---|---------|
| Thota et al (2020) | Lipid profile in diabetic subjects: a randomized clinical trial | Australia | RCT | I = 15 | Type 2 DM patients | C = 176.0±61.56 | HbA1C (%) | I = 7.31±1.54 | C = 9±2.33 | HbA1C (%) | I = 6.5±0.7 | C = 7±0.6 |
| Vanaie et al (2020) | Curcumin as a major active component of turmeric attenuates proteinuria in patients with overt diabetic nephropathy | Iran | RCT | I = 27 | Nephropathy type 2 DM patients | 1500 mg of curcuma longa extract per day for 10 weeks | Placebo | GDP (mg/dL) | I = 186.92±81.30 | C = 214.05±93.64 |
a. Forest Plot of *Curcuma longa* on fasting blood sugar levels

![Forest Plot](image1)

**Figure 3.** Forest plot of the effect of *Curcuma longa* rhizome extract on reducing fasting blood sugar levels

b. Funnel plot of *Curcuma longa* on fasting blood sugar levels

![Funnel Plot](image2)

**Figure 4.** Funnel plot of the effect of *Curcuma longa* rhizome extract on reducing fasting blood sugar levels
The results of the meta-analysis are seen in Figure 3. For high and low doses, giving curcuma long extract reduced fasting blood sugar levels by 0.48 compared to placebo and it was statistically significant. The heterogeneity of the research data showed $\Gamma^2 = 44\%$ so that the distribution of the data was stated as homogeneous. Subgroup analysis at high doses could reduce fasting blood sugar levels by 0.42 compared to placebo. Whereas subgroup analysis at low doses can reduce fasting blood sugar levels by 0.59 compared to placebo or greater than high doses.

Based on the funnel plot of Figure 4, the overall data from high doses and low doses shows bias because there are more plots on the right. The high dose subgroup showed a publication bias which was characterized by asymmetry of the right and left plots where 4 plots were on the right, 2 plots were on the left and 1 plot touched the line. Meanwhile, the low dose subgroup showed no publication bias which was indicated by the symmetrical plot of the right and left where 1 plot was on the right, 1 plot was on the left and 2 plots touched the line. The plot on the left of the graph appears to have a standard error between 0.1 and 0.4 and the plot is on the right.

Based on the funnel plot of Figure 4, the overall data from high dose and low dose shows bias because there are more plots on the right. The high dose subgroup showed a publication bias which was characterized by asymmetry of the right and left plots where 4 plots were on the right, 2 plots were on the left and 1 plot touched the line. Meanwhile, the low dose subgroup showed no publication bias which was indicated by the symmetrical plot of the right and left where 1 plot was on the right, 1 plot was on the left and 2 plots touched the line. The plot on the left of the graph appears to have a standard error between 0.1 and 0.4 and the plot is on the right.

**c. Forest Plot of Curcuma longa on HbA1C levels**

| Study or Subgroup | Curcumin | Placebo | Std. Mean Difference IV, Random, 95% CI | Std. Mean Difference IV, Random, 95% CI |
|-------------------|----------|---------|----------------------------------------|----------------------------------------|
|                   | Mean     | SD      | Total | Mean     | SD      | Total | Weight |                      |                          |
| 2.1.1 High Dose   | 7.04     | 0.98    | 39    | 7.22     | 1.69    | 36    | 10.1%  | -0.19 (-0.64, 0.37)  |                          |
| Akter et al. 2020 | 8.3      | 1.14    | 14    | 8.5      | 0.99    | 14    | 5.1%   | -0.51 (-1.26, 0.24)  |                          |
| Asadi 2016        | 8.8      | 2.1     | 40    | 9.1      | 1.6     | 40    | 10.5%  | -0.19 (-0.80, 0.38)  |                          |
| Chuangsermsen 2014| 6.5      | 0.5     | 107   | 7.1      | 1.1     | 106   | 15.7%  | -0.50 (-0.77, -0.22) |                          |
| Hidael 2019       | 11.2     | 3.2     | 21    | 11.4     | 1.8     | 23    | 23.3%  | -0.05 (-0.64, 0.54)  |                          |
| Thoa 2016         | 6.5      | 0.7     | 15    | 6.6      | 0.6     | 16    | 5.4%   | -0.75 (-1.48, -0.03) |                          |
| Subtotal (95% CI) | 236      | 235     | 54.1% | -0.36 (-0.54, -0.18) |                          |

Heterogeneity: $\tau^2 = 0.00$; $df = 4.83$, $df = 5$ ($P = 0.46$); $I^2 = 0$
Test for overall effect: $Z = 5.87$ ($P = 0.0001$)

| Study or Subgroup | Curcumin | Placebo | Std. Mean Difference IV, Random, 95% CI | Std. Mean Difference IV, Random, 95% CI |
|-------------------|----------|---------|----------------------------------------|----------------------------------------|
|                   | Mean     | SD      | Total | Mean     | SD      | Total | Weight |                      |                          |
| 2.1.2 Low Dose    | 8.2      | 0.5     | 15    | 8.2      | 0.3     | 17    | 5.8%   | -0.00 (-0.80, 0.80)  |                          |
| Mokhtar 2019      | 8.3      | 2.2     | 28    | 8.1      | 1.7     | 26    | 0.0%   | -0.13 (-0.45, 0.25)  |                          |
| Na 2012           | 7.2      | 2.5     | 50    | 7.9      | 2.9     | 50    | 11.7%  | -0.40 (-0.73, -0.08) |                          |
| Panahi 2017       | 6.5      | 1.0     | 50    | 7.5      | 0.8     | 50    | 11.2%  | -0.88 (-1.29, -0.47) |                          |
| Rahimi 2019       | 7.3      | 1.64    | 35    | 7.3      | 2.33    | 35    | 9.3%   | -0.85 (-1.34, -0.35) |                          |
| Subtotal (95% CI) | 17/5     | 177     | 45.9% | -0.44 (-0.82, -0.06) |                          |

Heterogeneity: $\tau^2 = 0.12$; $df = 11$, $df = 4$ ($P = 0.02$); $P = 66$
Test for overall effect: $Z = 2.29$ ($P = 0.02$)

| Total (95% CI) | 411     | 412     | 100.0% | -0.40 (-0.59, -0.20) |                          |

Heterogeneity: $\tau^2 = 0.04$; $df = 17$, $df = 10$ ($P = 0.06$); $P = 43$
Test for overall effect: $Z = 3.02$ ($P = 0.001$)
Test for subgroup differences: $Ch^2 = 0.15$, $df = 1$ ($P = 0.70$); $P = 0$

*Figure 5. Forest plot of the effect of Curcuma longa rhizome extract on HbA1C levels*
c. Funnel plot of *Curcuma longa* on HbA1C levels

![Funnel plot of the effect of Curcuma longa rhizome extract on reducing HbA1C levels](image)

The results of the meta-analysis seen in Figure 5 for the overall dose decreased HbA1C levels by 0.44 compared to placebo and were statistically significant. The overall heterogeneity of the data $I^2 = 43\%$ or homogeneous but in the low dose subgroup $I^2= 66\%$ or heterogeneous. The high-dose subgroup analysis reduced HbA1C by 0.36 compared to placebo and was statistically significant. Subgroup analysis regarding low doses in type 2 DM patients reduced fasting blood sugar levels by 0.44 compared to placebo and was statistically significant and not statistically significant.

Based on the funnel plot of Figure 6, the high-dose subgroup shows no publication bias which is indicated by symmetrical plots on the right and left, where 3 plots are on the right, 3 plots are on the left. Meanwhile, the low dose subgroup showed no publication bias, which was indicated by a symmetrical plot on the right and left, where 2 plots were on the right, 2 plots on the left and 1 plot touched the line. The plot on the left of the graph appears to have a standard error between 0.1 and 0.4 and the plot on the right has a standard error between 0.2 and 0.4.

**DISCUSSION**

Diabetes mellitus is a metabolic disease characterized by hyperglycemia. Diabetes mellitus is currently the number one non-communicable disease and the number four or five cause of death in various countries (WHO, 2019). Diabetes Mellitus Type 2 generally occurs due to conditions of insulin resistance and or reduced insulin secretion. This will cause symptoms in the form of polyuria, polydipsia and polyphagia. Diabetes Mellitus conditions that are not treated with controlled therapy can
increase the risk of macrovascular and microvascular complications. One of the parameters that need to be considered in diabetes mellitus therapy is blood glucose parameters. In the blood glucose parameters that are commonly used are fasting blood sugar and HbA1C parameters (Nam et al, 2017).

**Effect of Curcuma Longa rhizome extract on reducing fasting blood sugar levels**

There are 12 research articles Randomized Controlled Trial as a source of meta-analysis of the effect of curcuma longa rhizome extract on fasting blood sugar levels. The analysis was carried out with the review manager 5.4 application, the results were interpreted in the form of a forest plot and a funnel plot.

The results of the meta-analysis of the RCT study showed that giving curcuma longa rhizome extract reduced the effect size of 0.48 compared to placebo on fasting blood sugar levels and was statistically significant (SMD=-0.48, 95% CI -0.61, -0.34, p<0.001). The heterogeneity of the research data shows I²= 44% so that the distribution of the data is declared homogeneous (fixed effect model).

The results in the high-dose subgroup analysis showed a decrease of 0.42 and were statistically significant (SMD=-0.42, 95% CI -0.59, -0.25, p <0.001). The results of this study are in line with the study by Chuengsamarn et al (2014) which involved 213 patients with type 2 diabetes for three months showing that patients who received high doses of curcuma long rhizome extract supplements at high doses had lower fasting blood sugar levels than those receiving placebo (SMD -0.50, CI 95% -0.77, -0.22).

The results in the low dose subgroup analysis showed a decrease of 0.59 and were statistically significant (SMD=-0.59, 95% CI -0.81, -0.36, p <0.001). The results of this study are in line with the study by Panahiet al (2017) which involved 100 patients. Type 2 diabetes mellitus for three months showed that patients who received curcuma long rhizome extract supplements at low doses had lower fasting blood sugar levels than those receiving placebo (SMD -0.56, 95% CI -0.96, -0.16).

**Effect of Curcuma Longa rhizome extract on reducing HbA1C levels**

There are 11 research articles with the Randomized Controlled Trial study design as a meta-analysis source of the effect of curcuma longa rhizome extract on HbA1C levels. The analysis was carried out with the review manager 5.4 application, the results were interpreted in the form of a forest plot and a funnel plot.

The results of the meta-analysis of the RCT study showed that giving curcuma longa rhizome extract reduced the effect size by 0.40 compared to placebo on HbA1C levels and was statistically significant (SMD= -0.40, 95% CI= -0.59, -0.20, p <0.001). The heterogeneity of the research data showed I²= 43%.

The results on the high dose subgroup analysis showed a reduction of 0.36 and were statistically significant (SMD=-0.36, 95% CI -0.54, -0.18, p <0.001). The results of this study are in line with the study by Chuengsamarn et al (2014) which involved 213 type 2 DM patients for three months showing that patients who received high doses of curcuma long rhizome extract supplements experienced lower levels of HbA1C than receiving placebo (SMD -0.50, CI 95% -0.77, -0.22).

The results on the low dose subgroup analysis showed a reduction of 0.44 and were statistically significant (SMD=-0.44, 95% CI -0.82, -0.06, p <0.001). The results of this study are in line with a study by Panahiet al (2017) involving 100 type 2 DM patients for three months showing that
patients who received curcuma longa rhizome extract supplements at low doses experienced a decrease in fasting blood sugar levels than those who received placebo (SMD -0.88, CI 95% -1.29, -0.47).

The dosage of curcuma longa rhizome extract ranges from 300 mg / day to 2100 mg/day. For high doses it has a range above 1000 mg/day. For low doses it has a range below 1000 mg / day.

From the subgroup analysis of high and low doses, the administration of Curcuma longa rhizome extract at low doses had a greater effect on the decrease compared to high doses. Because the dosage effectiveness test (ED50) of rinpang curcuma longa extract on fasting blood sugar and HbA1C levels has not been found, there are no reinforcing data to conclude that the appropriate dose is used in reducing fasting blood sugar and HbA1C levels.

The fall in blood sugar levels is influenced by increased insulin secretion and increased insulin sensitivity. It occurs because the active ingredient curcuminoid in curcuma longa functions to repair pancreatic β cells and stimulate increased insulin secretion. The effect of increasing insulin sensitivity can also occur due to the influence of curcuminoids.

**ACKNOWLEDGEMENT**

We are very grateful to the database providers PubMed, Google Scholar, Science-direct, BMJ, and Springer Link.

**REFERENCE**

Adab Z, Shojaii A, Reza M, Iraj V, Eghtesadi S, Haqqani (2019). Effect of turmeric on glycemic status, lipid profile, hs-CRP, and total antioxidant capacity in hyperlipidemic type 2 diabetes mellitus patients. Phytother Res. 33(4): 1173-1181. https://doi.org/10.1002/ptr.6312.

Alvarenga L, Salarolli R, Cardozo LF, Santos R, Brito JS, Ann J, Reis D (2020). Impact of curcumin supplementation on expression of inflammatory transcription factors in hemodialysis patients: A randomized, double-blind, controlled study. Clin Nutr. 39(12): 3594-3600. https://doi.org/10.1016/j.clnu.2020.03.007.

Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S (2012). Curcumin extract for prevention of type 2 diabetes. Diab Care. 35(11):2121–2127. https://doi.org/10.2337/dc12-0116.

Hodaei H, Adibian M, Nikpayam O, Hedayati M, Sohrab G (2019). The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: a randomized, double-blind clinical trial. Diabetol Metab Syndr. 11:41. https://doi.org/10.1186/s13098-019-0437-7.

Jimenez G, Alvarez-mej AE, Salazar SJ (2016). The effect of dietary supplementation with curcumin on redox status and Nrf2 activation in patients with nondiabetic or diabetic protein-uric chronic kidney disease. J Ren

---

**AUTHOR CONTRIBUTION**

This study is self-funded.

**CONFLICT OF INTEREST**

Riska is the main researcher who selects the topic, explores and collects research data. Didik and Hanung played a role in analyzing data and reviewing research documents.

**FUNDING AND SPONSORSHIP**

There is no conflict of interest in this study.
Nutr. 26(4):237-44. https://doi.org/10.1053/j.jrn.2016.01.013.

Lim TK (2016). Edible medicinal and non-medicinal plants: Volume 12, modified stems, roots, bulbs. Medicin. 1(2): 196-204.

Mirzabeigi P, Mohammadpour AH, Sarrafar M, Gholami K, Mojtahedzadeh M, Javadia MR (2015). The effect of curcumin on some of traditional and non-traditional cardiovascular risk factors: A pilot randomized, double-blind, placebo-controlled trial. Iran J Pharm Res. 199(6):479–486. https://www.ncbi.nlm.nih.gov/pubmed/25901155.

Mokhtari M, Razzaghi R, Momen-Heravi M (2020). The effects of curcumin intake on wound healing and metabolic status in patients with diabetic foot ulcer. Phytother Res. 8(1): 1–9. https://doi.org/10.1002/ptr.6957.

Na L, Li Y, Pan H, Zhou X, Sun D, Meng M, Li X (2013). Curcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trial. Mol Nutr Food Res. 57(9):1569-77. https://doi.org/10.1002/mnfr.201200131.

Nam HC, Joses K, Jean CM, Katherine O, Leonor GW (2017). Standard Medical Care in Diabetes Eighth edition IDF Diabetes Atlas, 8th edition. World: IDF.

Panahi Y, Khalili N, Sahebi E, Namazi S, Simental-Mendia LE, Majeed M, Sahebkar A (2018). Effects of curcuminoids plus piperine on glycemic, hepatic and inflammatory biomarkers in patients with type 2 diabetes mellitus: A randomized double-blind placebo-controlled trial. Drug Res (Stuttg). 68(7): 403-409. https://doi.org/10.1055/s-0044-101752.

Perkumpulan Endokrinologi Indonesia (2015). Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia. PERKENI: Jakarta

Perkumpulan Endokrinologi Indonesia. (2019). Pedoman pengelolaan dan pencegahan diabetes mellitus tipe 2 dewasa di Indonesia (Guidelines for the management and prevention of adult type 2 diabetes mellitus in Indonesia). PERKENI: Jakarta

Rahimi HR, Mohammadpour AH, Dastani M, Jaafari MR, Abnous K, Mobarhan MG, Oskuee RK(2013). The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. J Chem Inf Model. 53(9): 1689–1699. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5052420/.

Riskesdas K (2018). Hasil Utama Riset Kesehatan Dasar (RISKESDAS) (Main Results of Basic Health Research (RISKESDAS). Journal of Physics. 44(8): 1–200.

Roxo DF, Arcaro CA, Gutierres VO, Costa MC, Oliveira JO, Lima TFO, Assis R (2019). Curcumin combined with metformin decreases glycemia and dyslipidemia, and increases paraoxonase activity in diabetic rats. Diabetol Metab Syndr. 11(1): 1–8. https://doi.org/10.1186/s13098-019-0431-0.

Shi J, Hu H, Harnett J, Zheng X, Liang Z, Wang YT, Ung COL (2019). An evaluation of randomized controlled trials on nutraceuticals containing traditional Chinese medicines for diabetes management: A systematic review. Chinese Med. 14(1): 1–20. https://doi.org/10.1186/s13020-019-0276-3.

Vanaie A, Shahidi S, Iraj B, Siadat ZD, Kabirzade M, Shakiba F (2019). Curcumin as a major active component of
Fatony et al. / Effect of *Curcuma Longa* Rhizome Extract on Fasting Blood Sugar Levels

Turmeric attenuates proteinuria in patients with overt diabetic nephropathy. J Res Med Sci. 24: 77. https://doi.org/10.4103/jrms.jrms_1055_18.

WHO (2019). Classification of diabetes mellitus. In Clinics in Laboratory Medicine. 21(1):168-179.